Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
indium-111-DOTA-girentuximab-IRDye800CW
- Development stage
- Phase 1
- Lead developer
- Radboud University Medical Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Indium-111-DOTA-girentuximab-IRDye800CW is a dual-modality imaging agent consisting of the chimeric monoclonal antibody girentuximab conjugated with both the radioisotope indium-111 and the near-infrared fluorescent dye IRDye800CW. This agent specifically targets carbonic anhydrase IX (CAIX), which is highly expressed in more than 95% of clear cell renal cell carcinomas (ccRCC). The dual-labeling approach allows for both preoperative imaging with SPECT/CT (using the radionuclide component) and intraoperative fluorescence imaging (using the fluorescent dye component), overcoming the limited penetration depth of light in biological tissue. This enables surgeons to initially locate tumors using radiodetection and then precisely delineate tumor margins using fluorescence imaging during surgical resection.
- Other names
- 111In-DOTA-girentuximab-IRDye800CWIndium-111-DOTA-girentuximab-IRDye800CWIndium111-DOTA-girentuximab-IRDye800CWIndium 111-DOTA-girentuximab-IRDye800CW
02
Targets
CA9 (Carbonic anhydrase IX)
Beyond the preview
Go deeper on indium-111-DOTA-girentuximab-IRDye800CW.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on indium-111-DOTA-girentuximab-IRDye800CW.